Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 0409-1703

This is a data table representing the proportion of patients taking Bortezomib and Dexamethasone after different time intervals. The first row indicates the time intervals (in days) and the second row indicates the corresponding number of patients remaining after each time interval. The table also displays a p-value obtained from the log-rank test.*

This appears to be a table showing data on patients and the proportion of them who received Bortezomib or Dexamethasone in a study. It includes the number of patients remaining at a certain time point and a p-value from a log-rank test. It is not possible to determine the context or purpose of the study from this limited information.*

This is a description of a pharmaceutical product presented in the form of a lyophilized vial containing 25 mg of bortezomib and 25 mg of mannitol commonly used for injection purposes. The sample also contains cautionary information about the contents of the medication and storage instructions. The recommended dose and additional prescribing documents should also be consulted before utilizing the product.*

This is a product information sheet for Bortezomib for Injection, which contains 25 g lyophilized powder along with 25 mg mannitol. The recommended dosage and storage information are provided, and the drug should be reconstituted before use. It can be administered intravenously or subcutaneously, and caution is advised due to the hazardous nature of the drug. The document also includes a lot number and manufacturing information.*

Bortezomib for Injection is a hazardous agent that comes in single-dose vial. It is intended for intravenous or subcutaneous use only and must be discarded if the unused portion is left. The manufacturer is Gland Pharma Limited in Andhra Pradesh, India, and it is distributed by Hospira, Inc, Lake Forest, USA. The product code is NDC 0409-1704-01. Unfortunately, no useful information is provided from the alphanumeric code.*

This is a description of Bortezomib medication provided in a single-dose vial containing 1 mg of the drug. It is meant for intravenous or subcutaneous use, and the unused portion should be discarded. The hazardous nature of the drug is indicated by a cautionary label. The medication is supplied in a lyophilized (freeze-dried) form, and the contents of the vial should be reconstituted before use. The recommended dosage and other information on the medication is available in the prescribing information. The drug manufacturer is Hospira, Inc. while the manufacturer of the substance is Gand Phama Limited, located in Andhra Pradesh, India. The label also provides information on how to reconstitute the medicine.*